Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y. Ichinose M, et al. Among authors: takizawa a. Int J Chron Obstruct Pulmon Dis. 2016 Aug 29;11:2017-27. doi: 10.2147/COPD.S110389. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27621608 Free PMC article. Clinical Trial.
Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.
Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, Takizawa A, Grönke L, Hirata K. Ichinose M, et al. Among authors: takizawa a. Adv Ther. 2017 Jul;34(7):1622-1635. doi: 10.1007/s12325-017-0554-3. Epub 2017 May 23. Adv Ther. 2017. PMID: 28537001 Free PMC article.
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Inoue Y, et al. Among authors: takizawa a. Respir Med. 2021 Oct;187:106574. doi: 10.1016/j.rmed.2021.106574. Epub 2021 Aug 12. Respir Med. 2021. PMID: 34564020 Free article. Clinical Trial.
Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
Ogura T, Suda T, Inase N, Nishioka Y, Azuma A, Okamoto M, Takizawa A, Ito T, Rohr KB, Inoue Y. Ogura T, et al. Among authors: takizawa a. Respir Investig. 2022 Nov;60(6):787-797. doi: 10.1016/j.resinv.2022.06.009. Epub 2022 Aug 1. Respir Investig. 2022. PMID: 35927208 Free article. Clinical Trial.
178 results